A 31-year-old male with no known medical illness presented with painless left eye protrusion for the past 2 years. Radiographic features were of an extraconal superior orbital mass with no invasion of adjacent structures. The patient underwent an excisional biopsy of the left superior extraconal mass a week later. The histopathological examination revealed a well-circumscribed lobulated mass with chondroid and myxoid stroma enveloping benign bland-appearing epithelial and myoepithelial cells. These pathological features were consistent with benign chondroid syringoma of the orbit. The patient had an uneventful recovery with no active ocular complaint post-operatively.Despite chondroid syringoma of the orbit being a rare tumour, it should be considered in the differential diagnosis of periorbital masses. Excision of the tumour remains the treatment of choice with histopathological examination as the gold standard of diagnosis. Regular follow-up is warranted in view of possible local recurrence or metastasis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/01676830.2019.1604766 | DOI Listing |
Int J Surg Case Rep
January 2025
Oral and Maxillofacial surgery Unit, Department of Dental and Maxillofacial Surgery, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Introduction: Pleomorphic adenoma, the most common benign salivary gland tumor, typically occurs in the parotid region but can also arise in minor salivary glands. Its occurrence in the lateral tongue is infrequent, making this case the first reported from Ethiopia and the second in English literature.
Case Presentation: We present an 11-year-old girl who underwent an excisional biopsy for a tongue swelling lasting 2 years.
Medicina (Kaunas)
December 2024
ENT Department, Carol Davila University of Medicine and Pharmacy, 050751 Bucharest, Romania.
: Carcinoma ex-pleiomorphic adenoma (CXPA) is a carcinoma derived from a primary or recurrent pleiomorphic adenoma. Microscopically, non-invasive CXPA (intracapsular and carcinoma in situ), minimally invasive CXPA (extracapsular invasion less than 1.5 mm), and invasive CXPA (extracapsular invasion more than 1.
View Article and Find Full Text PDFBeijing Da Xue Xue Bao Yi Xue Ban
February 2025
Department of Oral & Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
Salivary gland tumor is one of the most common tumors in oral and maxillofacial regions. The diagnosis and treatment of salivary gland tumors had been a clinical characteristic project in Peking University School and Hospital of Stomatology since long time ago. Here we introduced the research progress in diagnosis and treatment of salivary gland tumors during the past 10 years.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Department of Maxillofacial Surgery, Dubrava University Hospital, Zagreb, Croatia
Myoepithelial carcinoma (MC) is a rare salivary gland malignancy that usually affects people over the age of 50. The incidence is similar in both men and women. MC might develop de novo or within a pre-existing benign myoepithelioma or pleomorphic adenoma.
View Article and Find Full Text PDFZhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
January 2025
Department of Otorhinolaryngology Head and Neck Surgery, Nasal Skull Base Surgery, the Affiliated Hospital of Qingdao University, Qingdao266000, China.
To analyze the clinical features of nasal pleomorphic adenoma and to share clinical insights into its diagnosis and treatment. This was a case series study. Clinical data of 12 patients with nasal pleomorphic adenoma, confirmed by histopathology, admitted to the Department of Otorhinolaryngology Head and Neck Surgery, Affiliated Hospital of Qingdao University from 2014 to 2023, were retrospectively analyzed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!